Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Illumina Inc. is selling its cancer test developer, Grail, following its series of antitrust conflicts. The company is a known maker of gene-sequencing machines, and on Sunday, Dec. 17, it revealed its decision to divest this unit, which it bought in 2021 for $7.1 billion.
According to The New York Times, Illumina's move to divest its Grail unit came two days after the company recently lost in a court battle. It made an appeal, but the federal court largely sided with the Federal Trade Commission when it upheld the antitrust regulator's ruling that Illumina must sell its Grail on antitrust grounds.
Obstruction in Europe
It was reported that Illumina's deal for Grail was also not cleared in Europe, and it has, in fact, faced a roadblock there, too. In September last year, the EU said it would block the acquisition. The company publicly admitted that it had been unsuccessful with its appeals for the Grail deal, and this has led to the decision to divest the start-up.
At any rate, the company's troubles started when it went ahead and purchased the cancer test developer despite the complaint from the U.S. FTC. The commission argued that the buyout would reduce innovation in the American market as well as increase prices.
Execution of Illumina's GRAIL's Sale
The biotechnology company, headquartered in San Diego, California, said that its sale of GRAIL is set to be executed via a third-party or capital markets transaction that is in line with the European Commission's (EU) divestiture order. Illumina aims to finalize the terms of the deal by the end of the second quarter of 2024.
"We are committed to an expeditious divestiture of GRAIL in a manner that allows its technology to continue benefitting patients," Illumina's chief executive officer, Jacob Thaysen, said in a press release. "The management team and I continue to focus on our core business and supporting our customers. I am confident in Illumina's opportunities and our long-term success."
Photo by: Illumina Press Release
